Novartis Access
-
Upload
adb-health-sector-group -
Category
Documents
-
view
20 -
download
1
description
Transcript of Novartis Access
-
Harald Nusser, Global Head Novartis Access
Bangkok, Asia Development Bank, January, 2016
Novartis Access
www.novartisaccess.com
Ida Marie PantigStamp
-
Noncommunicable diseases disproportionally affect low- and middle-income countries
Sources: WHO Fact Sheet noncommunicable diseases, January 2015
Noncommunicable diseases prematurely take 16 million lives annually, WHO urges more action, January 2015
28m deaths every year in low- and
middle-income countries (LMICs)
82% of NCD deaths
in LMICs are caused by
CARDIOVASCULAR
DISEASES
CANCERS
RESPIRATORY
DISEASES
DIABETES
accounting for
nearly 75% of global NCD deaths
80%
of the global disease burden will be due to NCDs
by 2020
1 | Novartis Access portfolio | Asia Development Bank, January, 2016 | Business Use Only
-
The Novartis mission
Discovering new ways
to extend and improve peoples lives
2 | Novartis Access portfolio | Asia Development Bank, January, 2016 | Business Use Only
-
We believe Corporate Responsibility must be closely linked to our business strategy
To deliver
better
patient
outcomes
Science-
based
innovation
In
growing
areas of
healthcare
KAE609 Coartem DT
Education Affordable
medicines
Developing markets
3 | Novartis Access portfolio | Asia Development Bank, January, 2016 | Business Use Only
-
Innovation doesnt just mean new drugs we must also innovate to improve access
Innovate business
model to
improve access
Address unmet
medical need with
new drugs
Innovation
4 | Novartis Access portfolio | Asia Development Bank, January, 2016 | Business Use Only
-
We dont have all the answers but we have an approach
Commercial
for profit
High Income
Poverty
Low Income
Middle Income
High Middle Income
Economic objective
Social objective
Income Segments
Social Business
Not-for-profit
Philanthropy
5 | Novartis Access portfolio | Asia Development Bank, January, 2016 | Business Use Only
-
Our contribution: Novartis Access
6
OUR AIM
TO HELP REVERSE THE TIDE OF NCDs
BY ENABLING GOVERNMENTS in low and lower middle income countries
TO PROVIDE BETTER CARE
FOR PATIENTS
| Novartis Access portfolio | Asia Development Bank, January, 2016 | Business Use Only
-
Novartis Access: Innovating our business model in low and lower middle income countries
7
DRIVE AVAILABILITY
AND AFFORTABILITY OF
HIGH-QUALITY MEDICINES
ENSURE
STANDARD OF CARE
Targeting four main chronic diseases
and breast cancer
Collaboration with governments and NGOs to ensure
patients are properly diagnosed and treated
CARDIOVASCULAR
DISEASES
BREAST
CANCER
RESPIRATORY
DISEASES
DIABETES
DIAGNOSIS TREATMENT
A portfolio of 15 medicines for governments, NGOs and other institutional customers
at USD 1 per treatment per month
| Novartis Access portfolio | Asia Development Bank, January, 2016 | Business Use Only
-
CARDIOVASCULAR
DISEASES
Hypertension
Dyslipidemia
Heart failure
DIABETES
BREAST CANCER
RESPIRATORY
DISEASES
Chronic Obstructive Pulmonary Disease
Asthma
A portfolio of NCD medicines selected to meet the greatest health needs
8
Significant health need Addressing top 7 causes of death in low and lower middle income countries
Medical relevance Offering most commonly used dosage form and products that are either:
On or belonging to a class included in the WHO Model List of Essential Medicines
Belong to the most frequently prescribed medicines in these disease areas
Lack of access programs Expanding access to medicine where only few programs currently exist
| Novartis Access portfolio | Asia Development Bank, January, 2016 | Business Use Only
-
30 countries identified for highest impact
9
30 COUNTRIES
Considered to be low- and low-
middle-income countries by:
Lack of access-to-medicine programs
and disproportionate impact
Essential set-up to make a launch
feasible
Local teams and partners on the
ground to support Novartis Access
High unmet NCD needs
Healthcare infrastructure
and/or NGO partnerships
Strong Novartis
presence
107 countries in
Access to Medicine index
| Novartis Access portfolio | Asia Development Bank, January, 2016 | Business Use Only
-
Collaborations are key to Novartis Access from consultation to implementation
10
Trusted partners in academia, scientific communities
and NGOs contribute throughout the development, launch
and implementation process:
First idea New social business model
Need Field expertise and impact projections
Portfolio Medical feedback on dosage form and essential medicines
Countries Greatest needs and impact, healthcare infrastructure
Partnerships Definition of common operating model
Implementation Adaptation of operating model
Learning for expansion
| Novartis Access portfolio | Asia Development Bank, January, 2016 | Business Use Only
-
Implementing Novartis Access on the ground main points for collaborations
Integrity of the distribution chain
Capacity building (screening, diagnosis, referral mechanisms, dosing and patient compliance to treatment)
Measurement of social impact (awareness, treatment availability and affordability)
11 | Novartis Access portfolio | Asia Development Bank, January, 2016 | Business Use Only
-
Novartis Access: Five Year Vision
Sustainable business approach
Proven impact
Trusted partnerships
12
Sustainable business approach
Proven impact
Trusted partnerships
| Novartis Access portfolio | Asia Development Bank, January, 2016 | Business Use Only
-
www.novartisaccess.com